Glycan excellence against cancer 

TACAs are attractive targets for novel immunotherapeutics against human cancers. Many TACAs are expressed during embryonic development but not under physiologic conditions in differentiated tissues. On tumors, in contrast, TACAs show very high expression levels, allowing to bring more therapeutic agents to the cancer cell.

We are a growing team of highly motivated scientists. We endorse the biotech spirit of problem solving and let the best idea win. Being innovative and focused is key to have fast decisions and optimized solutions for our early pipeline.

Located in one of Berlin's prestigious science hubs, we offer a vibrant research environment at the forefront of antibody drug development.

Please follow the link for current job offers.

Unsolicited applications are welcome!